Published in Vaccine Weekly, May 26th, 2004
PT-100, which represents one of a family of compounds, appears to induce robust CD4+ and CD8+ T cell responses and potentially provide durable immunity.
"I am pleased to announce the initiation of the company's second development program," said Don Kiepert, president and chief executive officer at Point Therapeutics.
"This preclinical program is in addition to our oncology program, where PT-100 is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly